JP5351756B2 - Transdermal preparation - Google Patents

Description

  The present invention relates to a transdermally absorbable preparation.

  Percutaneous absorption preparations are preparations that are applied to the skin for a certain period of time and are treated by directly absorbing the drug from the application surface. This preparation has been widely used for many years as a local therapeutic agent such as an anti-inflammatory analgesic, a skin disease tape, an antipruritic patch, and a wound preparation. Furthermore, in recent years, the use as a transdermal therapeutic system, which is a systemic therapeutic drug, has attracted attention. Examples of the products using the transdermal therapeutic system include an angina pectoris agent, a menopause agent, a smoking cessation aid agent, and the like.

With respect to the percutaneous absorption-type preparations, preparations with higher sticking performance are required due to the diversification of uses as described above. In particular, since the improvement in stretchability of the support layer constituting the transdermal absorption-type preparation has a great influence on the adhesiveness of the preparation, various studies have been made on the constituent material of the support layer. For example, as shown in Patent Documents 1 to 3, proposals have been made to use a highly stretchable material such as an elastomer for the support layer.
Japanese Patent No. 3525391 JP-A-9-255567 JP-A-8-206151

  The percutaneous absorption-type preparation needs to have high stretchability to follow the movement of the applied skin and the like, but at the same time, it must also have sufficient adhesion to the skin. However, in the known techniques including the above documents, there is no disclosure about high stretchability and high adhesion, and it was necessary to improve both stretchability and adhesion in order to carry out.

  Accordingly, an object of the present invention is to provide a percutaneous absorption type preparation using an elastomer for a support layer, and having excellent adhesion without impairing stretchability.

  In order to achieve the above object, the present invention provides a transdermal preparation having a pressure-sensitive adhesive layer on a support layer, wherein the support layer includes at least an elastomer and a filler, and the pressure-sensitive adhesive layer includes at least a pressure-sensitive adhesive. A transdermally absorbable preparation comprising a base and a drug is provided.

  In the present invention, by further containing a filler in the support layer containing an elastomer, a percutaneous absorption-type preparation with improved adhesion can be obtained without impairing high stretchability. When the support layer contains an elastomer, the stretchability of the percutaneous absorption-type preparation is ensured, but by adding a filler to the support layer, the stretchability is not impaired, and the percutaneous absorption type The adhesion of the preparation to the skin is improved.

  The elastomer of the support layer and the adhesive base of the adhesive layer are preferably made of different polymers. By changing the type of elastomer and adhesive base polymer in the support layer, the permeation and diffusion of polymers and additives contained in the support layer and the adhesive layer is suppressed, and the shape stability of the percutaneous absorption type preparation is improved. By being maintained, high stretchability and high adhesion can be maintained for a long time.

  The filler in the support layer is preferably contained in an amount of 20 to 60% by mass relative to the total mass of the support layer. By setting the filler content within this range, not only the high adhesion improvement effect of the percutaneous absorption type preparation can be obtained, but also the moisture permeability of the whole preparation can be increased, and the percutaneous absorption has low skin irritation. Mold formulation can be provided.

  The filler is preferably composed of at least one of calcium carbonate and silicon dioxide. By selecting these substances as the filler for the support layer, a higher adhesion improving effect can be obtained, and a transdermal absorption-type preparation excellent in sticking property can be provided.

  The support layer preferably further contains a drug. Providing a percutaneous absorption preparation that allows the drug to be transferred from the adhesive base layer to the skin effectively by containing the drug in the support layer, and maintains high transdermal absorbability in addition to high adhesion. become able to.

  ADVANTAGE OF THE INVENTION According to this invention, it is a percutaneous absorption type formulation which used the elastomer for the support body layer, Comprising: The transdermal absorption type formulation excellent in adhesiveness without impairing a stretching property is provided.

It is a figure which shows the water vapor transmission rate of the transdermal absorption type preparation of Examples 5-7. It is a figure which shows the drug permeability of the percutaneous absorption type preparation of Examples 1-3 and Comparative Example 1.

  Hereinafter, preferred embodiments of the patch of the present invention will be described in detail. In the present specification, “%” means “mass%” unless otherwise specified.

  The transdermally absorbable preparation according to the embodiment comprises an adhesive layer containing at least an adhesive base and a drug on a support layer containing at least an elastomer and a filler. The pressure-sensitive adhesive layer may be formed on both sides of the main surface of the support layer or may be formed on one side.

  The elastomer constituting the support layer is not particularly limited as long as it is a polymer elastomer having elasticity at room temperature, and examples thereof include natural rubber and synthetic rubber, and synthetic rubber includes thermoplastic elastomer. Examples of the synthetic rubber include polyisobutylene, isoprene rubber, styrene-butadiene rubber, silicone rubber, styrene-isoprene-styrene copolymer, styrene-butadiene-styrene copolymer, and among these, polyisobutylene, Styrene-isoprene-styrene copolymer, styrene-butadiene-styrene copolymer and the like function as a thermoplastic elastomer.

  These elastomers may be used alone or in combination of two or more. For example, it is preferable to use a combination of a styrene-isoprene-styrene copolymer and polyisobutylene because the transferability of the drug to the skin and the physical properties of the preparation tend to be further improved. Examples of the styrene-isoprene-styrene copolymer include a styrene-isoprene-styrene copolymer (trade names: Clayton D-1107 and Clayton D-1111) manufactured by Kraton Polymer, and a styrene-isoprene manufactured by Nippon Synthetic Rubber. -Styrene copolymers (trade names: JSR5002, JSR5200), styrene-isoprene-styrene copolymers (trade names: QUINTAC 3421, 3520, 3570) manufactured by Nippon Zeon Co., Ltd., and the like. Examples of polyisobutylene include polyisobutylene (trade name: Vistanex) manufactured by ExxonMobil.

  As a density | concentration of an elastomer, 10 to 90% is preferable with respect to the support body layer total mass, and 15% to 85% is more preferable. If it is less than 10%, the support layer tends to break, and if it exceeds 90%, the stretchability tends to decrease and the adhesion of the transdermal preparation tends to decrease.

  The filler contained in the support layer is not particularly limited as long as it has the effects of the present invention, but calcium carbonate, magnesium carbonate, silicon dioxide, silicate (eg, aluminum silicate, magnesium silicate, etc.), Examples thereof include silicic acid, barium sulfate, calcium sulfate, calcium zincate, zinc oxide, and titanium oxide. Among these, it is preferable to consist of at least one of calcium carbonate and silicon dioxide, and by adopting these, the adhesion improving effect according to the present invention can be enhanced.

  As a density | concentration of a filler, 20 to 60% is preferable with respect to the support body total mass, and 25 to 55% is more preferable. If it is less than 20%, the effect of improving adhesion is small, and if it exceeds 60%, the support layer tends to break. By including a filler in the support layer, it is considered that the improvement of the slipping property against an external stimulus is also involved in the improvement of the adhesion.

  The support layer preferably further contains a drug. By including the drug in the support layer as well as the pressure-sensitive adhesive layer, the skin permeability and release of the drug are prevented from being lowered, and in addition to high adhesion, it has the effect of maintaining high transdermal absorbability. The drug is not particularly limited as long as it is absorbed through the skin and exerts a pharmacological effect. For example, an antiemetic (eg, granisetron, azasetron, ondansetron, ramosetron, etc.), a frequent urine treatment (eg: Oxybutynin, etc.), angiotensin I converting enzyme inhibitors (eg, captopril, delapril), Ca antagonists (eg, nifedipine), coronary vasodilators (eg, diltiazem, nicorandil), local anesthetics (eg, lidocaine, procaine) Etc.), thymic hormones (eg, serum thymic factor), muscle relaxants (eg, tizanidine, eperisone, dantrolene, etc.), stimulant stimulants, antihypertensive agents (eg, alprenolol, nifedipine, etc.), antitumor agents, psychotropic Drugs (eg, imipyramine, fentanyl, morphine, etc.), antibiotics, antiparkinsonian agents (eg, amantadine, levodopa) ), Antihistamines, anti-vertigo (eg, diphenidol, betahistine, etc.), hypnotic sedatives, anti-inflammatory analgesics (eg: indomethacin, ketoprofen, diclofenac, ibuprofen, flurbiprofen, felbinac, ketorolac, etc.), autonomic nerve agents, Cardio / vascular system drugs (eg, benzothiazepine), antitussive expectorant (eg, ketotifen, tulobuterol, tranilast, etc.), cerebral circulation metabolism improvers (eg, vinpocetine, etc.), vitamins, polypeptide hormones ( Root-initiating hormone-releasing hormone, thyrotropin releasing hormone, etc., peripheral vasodilators, immunomodulators (eg, polysaccharides, auranofin, lobenzarit, etc.), abducts (eg, ursodesoxychol) Acids, etc.), diuretics (eg hydroflumethia) De, etc.), antidiabetic agents (e.g. tolbutamide, etc.), gout therapeutic agent (e.g., drugs and their salts, such as colchicine, etc.) can be used. Among these, at least one can be selected and used depending on the purpose of treatment.

  The compounding amount of the drug in the support layer is preferably from 0.1 to 20%, particularly preferably from 1 to 10%.

  The support layer may contain additional components such as a tackifier, a softener, and an antioxidant as necessary.

  Examples of the tackifier include rosin derivatives (rosin, glycerin ester of rosin, hydrogenated rosin, glycerin ester of hydrogenated rosin, pentaerythrester ester of rosin), alicyclic saturated hydrocarbon resins (Arcon P90, P100). (Arakawa Chemical Industries, Ltd.)), aliphatic hydrocarbon resins (Quinton B-170 (Nippon Zeon), etc.), terpene resins (Clearon P-125, M-115, YS Resin RX1150 (Yasuhara Chemical)) Etc.), and maleic acid resins.

  Examples of the softening agent include liquid paraffin, polybutene, castor oil, cottonseed oil, palm oil, coconut oil, and process oil.

  As the antioxidant, tocopherol and an ester derivative thereof, ascorbic acid, ascorbic acid stearate, nordihuman logayaretinic acid, dibutylhydroxytoluene (BHT), and butylhydroxyanisole are preferable.

  The additive component is appropriately blended within a range of preferably 10% or less, more preferably 5% or less, particularly preferably 2% or less, based on the total mass of the support layer.

  The thickness of the support layer is preferably in the range of 20 to 150 μm, more preferably 30 to 130 μm. If the thickness is less than 20 μm, it is easy to break due to insufficient strength, and if it exceeds 150 μm, it is too hard and the stretchability is insufficient.

  The pressure-sensitive adhesive layer formed on the above support layer is not particularly limited as long as it contains at least a pressure-sensitive adhesive base and a drug, has adhesiveness, can be applied to the skin, and has the ability to release the drug.

  As the adhesive base constituting the adhesive layer, natural rubber, polyisoprene, isoprene rubber, polyisobutylene, silicone rubber, styrene-butadiene rubber, styrene block copolymer (styrene-isoprene-styrene copolymer, styrene- Butadiene-styrene copolymer, etc.) and a polymer of a monomer having a (meth) acryloyl group (hereinafter simply referred to as “acrylic polymer”). As the acrylic polymer, a copolymer of (meth) acrylic acid and (meth) acrylic acid ester is preferable, and the (meth) acrylic acid ester in the copolymer is (meth) acrylic acid having 4 to 18 carbon atoms. The alkyl ester is preferably (preferably 4 to 10, more preferably 4 to 8). When silicone rubber is used as the adhesive base, it is preferable to use a silicon-based tackifier such as MQ resin in combination, and when styrene-isoprene copolymer or styrene block copolymer is used as the adhesive base. Is preferably used in combination with the above-described tackifier (organic type). An adhesive base may be used individually by 1 type, or may be used in combination of 2 or more type.

  The adhesive base contained in the adhesive layer and the elastomer contained in the support layer are preferably made of different polymers. More preferably, the adhesive base and the elastomer have different SP (solubility parameter) values. When the SP value is different, stickiness of the support layer due to the permeation and diffusion of the additive can be prevented. From such a viewpoint, for example, when a styrene-isoprene-styrene copolymer is used as the elastomer of the support layer, the SP value is different from that of the styrene-isoprene-styrene copolymer as the adhesive base of the adhesive layer. It is preferable to use an acrylic polymer (preferred examples are as described above).

  In addition, the difference between the SP value of the elastomer of the support layer and the SP value of the polymer contained in the pressure-sensitive adhesive layer is preferably 0.5 to 4, more preferably 0.5 to 2. In such a range, the drug release property is improved.

  In addition, SP (solubility parameter) value here is a parameter | index which concerns on the polarity of a substance, and is related empirically with the mutual solubility of many chemical species. This SP value is calculated according to the description of the solubility parameter δ in the chemical handbook application edited by the Chemical Society of Japan (published in 1973) and Polymer Handbook (4th edition, edited by Johannes Brandrup and E. H. Immergut, published in 1998). be able to. Moreover, in the case of a copolymer, let the geometric value of SP value of each substance be SP value.

  The drug contained in the pressure-sensitive adhesive layer is preferably the same as that contained in the support layer. The compounding amount of the drug in the pressure-sensitive adhesive layer is not particularly limited as long as it is a transdermal absorption and exhibits a pharmacological effect, but is preferably 0.1 to 20% based on the total mass of the pressure-sensitive adhesive layer. -10% is particularly preferred.

  Furthermore, you may mix | blend additive components, such as an antioxidant, a filler, a plasticizer, a crosslinking agent, antiseptic | preservative, and an ultraviolet absorber, with an adhesive layer as needed. The additive component is appropriately blended within a range of preferably 10% or less, more preferably 5% or less, particularly preferably 2% or less, based on the total mass of the pressure-sensitive adhesive layer.

  In the present invention, the support layer preferably contains the above-mentioned drug in addition to the elastomer and the filler. An adhesive layer is formed on the support layer, and the adhesive layer contains an adhesive base and a drug, but the elastomer and drug in the support layer and the adhesive base and drug in the adhesive layer are: It is preferable to have the following relationship. That is, the drug in the support layer and the drug in the pressure-sensitive adhesive layer are of the same type, and the solubility of the drug in the elastomer constituting the support is such that the drug in the pressure-sensitive adhesive base constituting the pressure-sensitive adhesive layer It is preferably lower than the solubility.

In order to satisfy such conditions, the difference in SP value between the elastomer and the adhesive base is preferably 0.5 to 4 (preferably 0.5 to 2) as described above. When the drug is a compound having a polar group, the SP value of the elastomer is preferably 0.5-4 (preferably 0.5-2) smaller than the SP value of the adhesive base, and the drug has a polar group. When it is a compound which does not have, it is preferable to make SP value of an elastomer 0.5-4 (preferably 0.5-2) larger than SP value of an adhesive base. Since most of the drugs are compounds having a polar group, the former relationship is more preferable. In order to realize the former relationship, natural rubber, polyisoprene, isoprene rubber, polyisobutylene, styrene-butadiene rubber, styrene block copolymer (styrene-isoprene-styrene copolymer) can be used as an elastomer for the support layer. It is preferable to use a polar polymer such as an acrylic polymer (preferred examples are as described above) as a pressure-sensitive adhesive base in the pressure-sensitive adhesive layer using a hydrocarbon-based elastomer such as a coalesced styrene-butadiene-styrene copolymer. . In order to realize the latter relationship, a polar polymer may be used as the elastomer and a hydrocarbon elastomer may be used as the adhesive base.

  When not only the pressure-sensitive adhesive layer but also the support layer contains a drug, the solubility relationship between the drugs in both layers is as described above (that is, the relationship between the SP value of the elastomer and the pressure-sensitive adhesive base is as described above). The transfer of the drug in the pressure-sensitive adhesive layer to the support layer is suppressed, and the amount of drug absorbed percutaneously increases. In addition, when not only the pressure-sensitive adhesive layer but also the support layer contains a drug, the content of the drug as a whole percutaneously absorbable preparation increases as compared with the case where the drug is contained only in the pressure-sensitive adhesive layer. The amount of drug absorbed by the skin increases and it can be used for a long time. Thus, by adopting the above preferred form, a transdermal preparation having not only high stretchability and excellent adhesion but also a marked improvement in the amount, time and efficiency of percutaneous absorption of the drug. can get.

  The thickness of the pressure-sensitive adhesive layer formed on the support layer is preferably 50 to 300 μm, more preferably 80 to 150 μm. In addition, when the thickness of the pressure-sensitive adhesive layer is less than 50 μm, the persistence of adhesiveness and adhesion tends to decrease, and when it exceeds 300 μm, the cohesive force and shape retention tend to decrease.

Furthermore, moisture permeability of the entire formulation ^is preferably in the range of ^{100g / m 2 · 24hr~300g / m} 2 · 24hr. This is because, within this range, drug absorption is good and skin irritation tends to be low.

  The percutaneous absorption type preparation may be provided with a release liner on the pressure-sensitive adhesive layer in order to protect the pressure-sensitive adhesive layer. As the release liner, those having sufficient peelability from the pressure-sensitive adhesive layer are used, and a polyethylene terephthalate (PET) film, a polyethylene film, a polypropylene film, a polytetrafluoroethylene film and the like can be used.

  The support layer of the transdermal preparation can be produced by a conventional method such as a solvent method or a hot melt method. For example, in the case of producing by a solvent method, an elastomer is melted, dispersed or swollen in an organic solvent, a filler or other components are added thereto, and after stirring, the organic solvent is removed to form a film. When the support layer is produced by a hot melt method, the elastomer is heated and melted, and a filler and other components are added thereto, stirred, and then extruded in a molten state using a T die or the like to form a film.

  The pressure-sensitive adhesive layer of the transdermal preparation can also be produced by a conventional method such as a solvent method or a hot melt method. For example, in the case of manufacturing by the solvent method, other components are added to the organic solvent solution of the adhesive base to be blended, stirred, and then spread on a release liner to remove the organic solvent and form an adhesive layer. Thereafter, a percutaneously absorbable preparation can be obtained by pasting it together with the support layer. In addition, when the adhesive base to be blended can be applied by the hot melt method, after the adhesive base is dissolved at a high temperature, other components are added, stirred, and spread on the release liner for adhesion. After forming the agent layer, a transdermal preparation can be obtained by pasting it together with the support layer. The release liner may be peeled off during the production process, or may be used as a backing material for the preparation and peeled off after the preparation is applied to the skin.

  EXAMPLES Hereinafter, although this invention is demonstrated more concretely based on an Example and a comparative example, this invention is not limited to a following example at all.

(Preparation of adhesive layer 1)
A mixture obtained by dissolving and mixing isopropyl myristate and tulobuterol in an ethyl acetate solution of Duro Tak 87-4098 (manufactured by National Starch Co., Ltd., SP value = 9 to 10), which is a tacky alkyl acrylate copolymer. After coating on a release liner, the solvent was removed by drying to obtain a pressure-sensitive adhesive layer 1 having a thickness of 50 μm. Table 1 shows the compounding ratio of the components contained in the pressure-sensitive adhesive layer 1. In addition, the numerical value of prescription shown in Table 1 points out "mass%".

(Preparation of adhesive layer 2)
Styrene-isoprene-styrene copolymer (SP value = 8 to 8.5), polyisobutylene (SP value = 7.8 to 8.0), Alcon P100 (Arakawa Chemical Industries, Ltd.) which is an alicyclic saturated hydrocarbon resin Manufactured), liquid paraffin, isopropyl myristate, and tulobuterol were dissolved and mixed in toluene, and the resulting mixture was applied to a release liner, and then the solvent was removed by drying to obtain an adhesive layer 2 having a thickness of 50 μm. Table 1 shows the compounding ratio of the components contained in the pressure-sensitive adhesive layer 2. In addition, the numerical value of prescription shown in Table 1 points out "mass%".

<Production of Examples 1 to 7>
A predetermined amount of each component shown in Table 2 was weighed, dissolved and mixed in toluene, and the resulting mixture was applied to a release liner, and then the solvent was removed by drying to obtain a support layer. The support layer and the pressure-sensitive adhesive layer 1 were bonded together to obtain the percutaneous absorption preparations of Examples 1 to 7. In addition, "%" in the numerical value of the prescription shown in Table 2 refers to "mass%".

<Production of Comparative Examples 1 to 3>
A predetermined amount of each component shown in Table 3 was weighed, dissolved and mixed in toluene, and the resulting mixture was applied to a release liner, and then the solvent was removed by drying to obtain a support layer. The support layer and the pressure-sensitive adhesive layer shown in Table 3 were bonded together to obtain the percutaneous absorption preparations of Comparative Examples 1 to 3. In addition, "%" in the numerical value of the prescription shown in Table 3 refers to "mass%".

<Production of Comparative Example 4>
A polyethylene terephthalate (PET) film and a pressure-sensitive adhesive layer shown in Table 3 were bonded together to obtain a percutaneous absorption type preparation of Comparative Example 4.

[Adhesion test by human]
For the percutaneous absorption type preparations of Example 4 and Comparative Example 3, the adhesion was evaluated by the following method. That is, the percutaneous absorption preparation punched out to 5 cm ² was used as a test piece, and the adhesion after being applied to the upper arm of three subjects (male / healthy person) for 24 hours was evaluated. The results are shown in Table 4. It was confirmed that the adhesion of the percutaneously absorbable preparation was improved by blending a filler with the support layer.
○: Adhering 70% or more Δ: Adhering 40-70%
X: Adhesion 40% or less

[Adhesion test with rabbits]
For the transdermal preparations of Examples 2 and 3 and Comparative Example 4, adhesion was evaluated by the following method. That is, a percutaneous absorption preparation punched out to 5 cm ² was used as a test piece, and was applied to the back skin of a rabbit previously treated with a clipper and a shaver for 48 hours. The results are shown in Table 5. Even when a filler was blended in the support layer, it was confirmed that the elasticity was higher than that of the PET film and the adhesion was improved.
○: Adhering 70% or more Δ: Adhering 40-70%
X: Adhesion 40% or less

[Observation of shape change]
The percutaneous absorption type preparations of Examples 1 to 3 and Comparative Example 2 were stored for one month in a thermostatic chamber at a temperature of 40 ° C. and a humidity of 75%, and the shape of the preparation (stickiness / exudation) was evaluated. The results are shown in Table 6. The transdermal absorption type preparations of Examples 1 to 3 in which the elastomer of the support layer and the adhesive base of the pressure sensitive adhesive layer are different from each other in comparison with the preparation of Comparative Example 2 using the same styrene-isoprene-styrene rubber copolymer. Improvement of the shape change was observed.

[Measurement of moisture permeability]
With respect to the percutaneous absorption type preparations of Examples 5 to 7, the moisture permeability at a temperature of 40 ° C. and a relative humidity of 90% was measured according to the cup method (JIS Z0208).

  That is, a sample punched out to a diameter of about 70 mm (n = 3), anhydrous calcium chloride (particle size passing through a standard sieve of 2380 μm and staying at 590 μm) as a hygroscopic agent, S. S tester No. 3525 (Yasuda Seiki Seisakusho) was used.

  A glass dish containing a hygroscopic agent was placed in a cup and placed on a cup table kept horizontal. Place the test piece in a concentric circle with the cup so that the support for the patch is on top, and cover the guide with the groove of the cup. The ring was pushed in until the test piece was in close contact with the upper edge of the cup according to the guide, a weight was placed on it, and then the guide was pulled up and removed carefully so that the ring did not move. Next, while rotating the cup horizontally, the molten sealing agent was poured into a groove around the cup, the edge of the test piece was sealed, and after the sealing agent solidified, the weight and the cup base were removed to obtain a test specimen. (N = 3)

After the initial mass of the cup was measured, the test specimen was left in a constant temperature and humidity apparatus maintained at 40 ° C. and a relative humidity of 90%, and taken out after 24 hours. The test body was stored in a desiccator for 30 minutes, and weighing was repeated twice to measure the mass of the cup. The value obtained by subtracting the initial mass from this mass was the increase amount, and the mass increase amount converted per 1 m ² was the moisture permeability (g / m ² · 24 hr). This operation was performed until 72 hours later, and the moisture permeability was determined every 24 hours. The results are shown in FIG. From FIG. 1, by making a filler into 20-60 mass% with respect to the support body layer total mass,
It was confirmed that higher moisture permeability was obtained.

[Drug permeability test]
For the percutaneous absorption type preparations of Examples 1 to 3 and Comparative Example 1, drug permeability was evaluated by the following method. Specifically, the percutaneously absorbable preparation was punched into 5 cm ² and used as a test piece, and the test piece was affixed to the dorsal skin of a hairless mouse (female 7 weeks old) using a Franz type diffusion cell, and adjusted to pH 7.2 at 37 ° C The adjusted phosphate buffer solution was sampled every 2 hours as a receptor solution, and the permeation amount of the drug (tulobuterol) was quantified. The results are shown in Table 7 and FIG.

Claims (3)

A percutaneous absorption-type preparation comprising a pressure-sensitive adhesive layer on a support layer,
The support layer includes at least an elastomer , calcium carbonate as a filler , and a drug ,
The pressure-sensitive adhesive layer is a transdermal preparation containing at least an adhesive base and a drug.   The transdermal absorption preparation according to claim 1, wherein the elastomer and the adhesive base are made of different polymers.   The transdermally absorbable preparation according to claim 1 or 2, wherein the filler is contained in an amount of 20 to 60% by mass based on the total mass of the support layer.

Images